EPIC-1042
EPIC-1042 is an orally active PTRF inhibitor. EPIC-1042 disrupts the PTRF/Cavin-1-caveolin-1 interaction and inhibits ubiquitination-mediated proteasomal degradation to preserve TAX1BP1. EPIC-1042 promotes the binding of p62 to PARP1 and p62-mediated degradation of PARP1, impairing base excision repair and MGMT recruitment. EPIC-1042 enhances Mitophagy, reduces ROS, and reduces Apoptosis. EPIC-1042 reduces infarct volume after reperfusion injury and improves neurological and cognitive outcomes. EPIC-1042 can be used for research on ischemic stroke and glioblastoma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 372180-55-7
- Formel: C20H26N6
- Molecular Weight:350.46
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[2]|
PARP1 |
MGMT |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
>10 μM
|
Cardiotoxicity against HEK293 cells by manual patch-clamp assay with IC50 greater than 10 μM.
Cardiotoxicity against HEK293 cells by manual patch-clamp assay with IC50 greater than 10 μM.
|
37651725 |
In Vitro
The effect of EPIC-1042 on sEV secretion depends on PTRF in GBM cells[2].
EPIC-1042 increases TMZ-induced O6MeG accumulation and DNA damage in MGMT-positive T98G and LN-18 cells[2].
EPIC-1042-enhanced O6MeG accumulation in T98G and LN-18 cells depends on p62-mediated PARP1 degradation[2].
EPIC-1042 blocks autophagic degradation rather than inducing autophagosome formation in U87-MG and TBD-0220 cells[2].
EPIC-1042 induces PARP1 protein degradation in U87-MG and TBD-0220 cells[2].
EPIC-1042 prevents OGD/R-induced decrease in TAX1BP1 protein without reducing Tax1bp1 mRNA levels in HT22 cells[1].
EPIC-1042 reduces OGD/R-induced TAX1BP1 ubiquitination and its proteasome-mediated degradation in HT22 cells[1].
EPIC-1042 (100 μM) binds PTRF in U87-MG and TBD-0220 cell lysates[2].
EPIC-1042 inhibits sEV secretion in U87-MG and TBD-0220 cells without markedly altering sEV size[2].
EPIC-1042 reduces sEV-mediated TMZ efflux and increases intracellular TMZ in TBD-0220 cells[2].
EPIC-1042 exhibits low cardiotoxicity in HEK293 patch-clamp experiments, with an IC50 > 10 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U87-MG and TBD-0220 cell lysates expressing PTRF-eGFP
-
Concentration:100 μM (EPIC-1042); 100 μM (EPIC-1042-Biotin)
-
Incubation Time:overnight at 4°C (primary incubation); 4 h at 4°C (streptavidin beads); 15 min total (3 washes)
-
Result:Streptavidin beads strongly pulled down endogenous PTRF and ectopic PTRF-eGFP in biotinylated samples; no signal was detected in non-biotinylated samples.
-
Cell Line:U87-MG and TBD-0220 cells
-
Concentration:5, 10, 20, 40 μM (dose response)
-
Incubation Time:8, 16, 24, 48 h (time course)
-
Result:Increased p62 and LC3-II levels in a dose- and time-dependent manner in U87-MG and TBD-0220 cells.
In Vivo
EPIC-1042 (15-45 mg/kg; p.o.; days 7-21) enhances TMZ efficacy in a dose-dependent manner, with higher EPIC-1042 doses yielding longer median survival in BALB/c nude mouse orthotopic TBD-0220 glioblastoma xenografts[2].
EPIC-1042 plus TMZ (HY-17364) reduces tumor burden in BALB/c nude mouse subcutaneous LN-18 glioblastoma xenografts, while EPIC-1042 alone does not clearly inhibit growth[2].
EPIC-1042 (15-30 mg/kg; i.g.; once daily; 3 days before MCAO/R and 3 days after MCAO/R) combined with Edaravone (HY-B0099) produces only marginal additional reduction in infarct area compared with either agent alone after cerebral I/R in C57BL/6 mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 8-10 weeks old)[1]
-
Dosage:15 mg/kg; 30 mg/kg
-
Administration:i.g.; once daily; 3 days before MCAO/R
-
Result:Pre-administration reduced neurological impairment measured by mNSS, rotarod, and corner turn tests.
TTC staining showed attenuated infarct volume after cerebral I/R injury, and H&E staining showed fewer disordered and necrotic cells in the hippocampal region compared with MCAO mice.
-
Animal Model:C57BL/6 (male, 8-10 weeks old)[1]
-
Dosage:15 mg/kg; 30 mg/kg
-
Administration:i.g.; once daily; 3 days before MCAO/R and 3 days after MCAO/R
-
Result:Alleviated neurological damage and reduced infarct size.
Subacute-phase death rates were 15% and 20%, compared with 50% in untreated mice.
In the Morris water maze, mice showed decreased latency to first platform crossing during training, increased platform-area crossings, and increased time spent in the target quadrant on the test day.
TAX1BP1 protein expression decreased in the ipsilateral hemisphere after ischemic stroke, and this decline was inhibited.
Increased neuronal LC3/lysosome/mitochondria co-localization, increased healthy mitochondria and early mitophagy by TEM, and reduced ROS levels and apoptosis in the ischemic hemisphere.\nAt 3 days post-modeling, neurological function did not differ significantly between the edaravone-combination group and the other groups.
The edaravone-combination group showed a marginally greater reduction in cerebral infarction area than the other groups.
-
Animal Model:BALB/c nude (female, 4 weeks old)[2]
-
Dosage:EPIC-1042 15 mg/kg; TMZ 5 mg/kg
-
Administration:p.o.; days 7-21; co-administered TMZ p.o.
-
Result:Slightly suppressed tumor growth and did not improve overall survival.
The greatest reduction in tumor burden by luminescence intensity occurred.
Median survival was about 1.5 times that of the TMZ-only group.
H&E staining showed the smallest tumor size, and Ki-67 staining was lower in the combination group.
-
Animal Model:BALB/c nude (female, 4 weeks old)[2]
-
Dosage:EPIC-1042 15, 30, or 45 mg/kg; TMZ 5 mg/kg
-
Administration:p.o.; days 7-21; co-administered TMZ p.o.
-
Result:Dose-dependent tumor growth inhibition by bioluminescence and prolonged survival occurred.
Median survival was 53 days at 15 mg/kg, 57 days at 30 mg/kg, and 62 days at 45 mg/kg with co-administered TMZ.
Immunohistochemistry showed decreasing PARP1 with increasing dose, increasing γ-H2AX, and reduced Ki-67.
Chemical Information
-
CAS. Nr. 372180-55-7
-
Molecular Weight 350.46
-
Formel C20H26N6
-
SMILES
NCCNC1=C(C#N)C2=C(C(NCC3=CC=CC=C3)=N1)CN(CC)CC2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- EPIC-1042
- 372180-55-7
- EPIC1042
- EPIC 1042
- p62
- PARP
- DNA/RNA Synthesis
- DNA Methyltransferase
- Mitophagy
- Reactive Oxygen Species (ROS)
- Apoptosis
- Sequestosome-1
- SQSTM1
- poly ADP ribose polymerase
- DNMTs
- DNA MTases
- Mitochondrial Autophagy
- Cavin-1
- PARP1
- PTRF
- TAX1BP1
- autophagic degradation
- caveolae
- caveolin-1
- exosome biogenesis
- extracellular vesicle secretion
- mitophagy
- Inhibitor
- inhibitor
- inhibit